Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti

Details Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti

1997-01-29

1998-07-14

Kumar, Shailendra

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

514 2, 514 5, 514616, 514559, 530300, 530329, 530331, 554 36, 554 37, 562433, 564153, A61K 31195, C07C22924

Patent

active

057805091

DESCRIPTION:

BRIEF SUMMARY
This application is a 371 of PCT/JP95/00997, filed May 24, 1995.
The present invention relates to a compound bearing at least two 2,6-diiodophenyl-4-yl groups having diagnostic activity of iodine allergy. This compound is useful for predicting adverse effect caused by using iodinated X-ray contrast media and other iodine containing drugs.
X-ray radiograms of the blood-vessel and the urinary tract were widely used today for the purpose of accurate understanding of the condition of diseases and better planning therapeutic programs. The X-ray radiograms are taken by X-ray irradiation just after administering iodinated radiocontrast media by vascular as well as nonvascular routes.
However, iodine-containing X-ray contrast media are known to cause the serious side effects such as shock due to iodine allergy during and after their administration.
Iodine containing drugs other than the X-ray contrast media have been developed and their adverse effects depend on iodine allergy are also known.
As described above, there are clinical problems that serious adverse effects like shock by iodine allergy might happen during and after the administration of iodinated X-ray contrast media. Therefore, the development of X-ray contrast media free from such adverse effects is desired. However, X-ray contrast media absolutely free from such adverse effects have not yet been developed today.
Thus, a small amount of an X-ray contrast medium is previously administered intravenously to a patient before the regular use of the X-ray contrast medium, in order to test for hypersensitivity, if any, to the medium. This pretest is deficient in reliability and there are examples in which side effects are either caused by the pretest amount or in the regular test even in the case of a negative result in the pretest, or in which no abnormality is caused in the regular test even in the case of a positive result in the pretest.
Thus, presently, there is no established method for predicting any severe adverse effects caused by iodine allergy to iodinated.drugs such as iodinated X-ray contrast media, and therefore highly reliable agents for easily diagnosing iodine allergy are desired.
It is possible to design in vivo diagnostic compounds of iodine allergy if a chemical structure of antigenic determinants is made clear. It has been known that immediate type hypersensitivity is provoked by cross-linking IgE antibodies by antigen on the surface of mast cells in the skin followed by releasing histamine and other biological active substances of allergy from the mast cells. Cross-linking of the IgE antibodies is possible by the compounds having at least two antigenic determinants in a molecule (Immunology page 265, Edited by Ivan M. Roitt, Jonathan Brostoff, and David K. Male; Gower Medical publishing Ltd. London, England, 1989). Therefore, iodinated proteins produced by reacting iodine to proteins have diagnostic activity of iodine allergy. However, these are immunogenic because of high molecular weight of these iodinated proteins. Accordingly, it is thought undesirable that an administration of the diagnostic agent of iodine allergy to a patient is simultaneously to sensitize the patient to iodine allergy.
In order to avoid this problem, we have designed the compounds having eliciting antigenicity of iodine allergy but not having sensitizing antigenicity.
We, the inventors of the present invention have studied to obtain agents for diagnosing iodine allergy from such a standpoint that the mechanism by which adverse effects caused by iodinated drugs such as iodinated X-ray contrast media is based on iodine allergy. During our study, however, we have experienced a problem that an administration of the diagnostic agent of iodine allergy to a patient is simultaneously to sensitize the patient to iodine allergy. In order to avoid this problem, we have found that compounds having elicitation antigenicity (antigenicity to elicit an allergic reaction) but not having sensitization antigenicity (antigenicity to induce antibody production or immune lymphocytes)

REFERENCES:
Immunology, Roitt et al pp. 264-265.
Synthesis and Applications of Isotopically Labeled Compounds Proceedings of an International Symposium,Heys et al Jun. 1982 pp. 425-426 Preparation of Tritiated Diethylstilbestrol and Related Compounds.
Experientia (1985), 41 (3), pp. 385-387 Bernard et al IgG purification to measure the level of an iodinated thyroglobulin etc.
Khim, Prom-st. (Moscow) 1989, (2), pp. 106-109.
Analytical Biochemistry 210, 129-135 (1993) Tsomides et al Stoichiometric Labeling of Peptides by Iodination on Tyrosyl or Histidyl Residues.
J. of Labelled Compounds and Radiopharmaceuticals vol. XVII, No. 6 pp. 901-909 Maurizis et al Marquage A Haute Activitie Specifique etc.

Affiliated with

Also associated with

Rating

Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound bearing two, 2,6-diiodophenol-4-YL groups and diagnosti will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1882252